Investors in biotech stocks Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) and Medivation (NASDAQ:MDVN) must be smiling from ear to ear, as each of these companies has been a monster winner for long-term investors. In the past 5 years alone both of these companies have gone up more than 10 times in value, leaving a comparable investment in the S&P 500 in the dust.
We Fools like to invest in stocks with a strong history of market thumping returns, so we asked our team of Motley Fool contributors to share their opinions on which one of these two companies is the better buy today.
Todd Campbell: In my view, it's Medivation that is the more intriguing of these two stocks.
Brian Feroldi: Medivation certainly looks like an interesting opportunity right now, but when forced to choose I think I'd give the slight edge to Jazz. Here's why.
Brian Feroldi has no position in any stocks mentioned. Todd Campbell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
2 Biotech Stocks that Turned $8,000 into over $250,000
An $8,000 investment in these biotech stocks 10 years ago would be worth over $250,000 today. Are more gains ahead?
Is Pfizer Paying Too Much to Buy Medivation?
Pfizer's forking out $14 billion in cash, but the deal significantly builds out the drugmaker's oncology lineup.
What's Up With Mylan's EpiPen Pricing?
An EpiPen pricing debacle, an unexpected FDA rejection, and a sticker-shock inspiring M&A deal led to wild moves in Mylan N.V., Portola Pharmaceuticals, and Medivation shares this week.